https://www.selleckchem.com/pr....oducts/cremophor-el.
2%). Antivirals with low aqueous solubility were more likely to have label recommendations and were more commonly investigated using clinical DDI studies (P less then 0.01). For recommendations informed by clinical DDI studies, changes in drug exposure were associated with actionable label recommendations (P less then 0.01). The frequency of exposure changes in clinical DDI studies was similar across antiviral indications, but exposure changes were numerically higher for antacids (71.4%) relative to PPIs (42.9%) and H2 blockers
Like
Comment
Share
